Mburu C N, Ojal J, Selim R, Ombati R, Akech D, Karia B, Tuju J, Sigilai A, Smits G, van Gageldonk P G M, van der Klis F R M, Flasche S, Kagucia E W, Scott J A G, Adetifa I M O
Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Vaccine. 2025 Aug 13;61:127425. doi: 10.1016/j.vaccine.2025.127425. Epub 2025 Jun 21.
Measles and rubella have been targeted for elimination by the World Health Organization. Age-specific population immunity to measles and rubella is important to assess progress towards elimination but data are scarce. We conducted seroprevalence surveys to identify disease-specific population immunity profiles in children and adults in Kilifi.
Sera from cross-sectional surveys in the Kilifi Health Demographic Surveillance System (2009-2021) were analysed using a fluorescent bead-based multiplex immunoassay. Bayesian multilevel regression with post stratification was used to obtain seroprevalence estimates adjusted for the underlying population and assay performance. Associations between seropositivity and age, sex, location and ethnic group were assessed using a mixed effects logistic regression.
Measles-adjusted seroprevalence showed a significant increase from 88 % in 2009 to 93 % in 2021 (τ = 0.875, P = 0.01). Seropositivity was significantly higher in all age groups compared to those under 9 months. Seroprevalence among children ineligible for the first measles vaccine dose (MCV1) remained low (10-57 %), whereas MCV1-eligible children (9-17 months) had higher seroprevalence (68-91 %). Adult measles seroprevalence exceeded 96 %. Rubella seroprevalence followed a similar pattern, with adults above 88 %. Following the MR campaign, measles seroprevalence increased from 92 % to 96 % in eligible children, while rubella seroprevalence rose from 45 % to 82 %.
Population immunity for measles significantly increased over the 12-year period suggesting improvement in immunisation program performance. To reduce reliance on frequent SIAs, efforts should focus on optimizing both the timing and coverage of routine doses, particularly ensuring higher coverage of MCV2. The introduction of rubella vaccination has positively impacted immunity in children. Sustaining this immunity is essential to prevent potential gaps in older age groups, which could increase the risk of Congenital Rubella Syndrome (CRS) in infants.
世界卫生组织已将麻疹和风疹列为消除目标疾病。特定年龄人群对麻疹和风疹的免疫力对于评估消除工作的进展很重要,但相关数据稀缺。我们开展了血清流行率调查,以确定基利菲儿童和成人中特定疾病的人群免疫状况。
使用基于荧光微球的多重免疫分析法对基利菲健康人口监测系统(2009 - 2021年)横断面调查的血清进行分析。采用分层后贝叶斯多级回归,以获得根据基础人群和检测性能调整后的血清流行率估计值。使用混合效应逻辑回归评估血清阳性与年龄、性别、地点和种族之间的关联。
经调整的麻疹血清流行率从2009年的88%显著增至2021年的93%(τ = 0.875,P = 0.01)。与9个月以下儿童相比,所有年龄组的血清阳性率均显著更高。不符合首剂麻疹疫苗(MCV1)接种条件的儿童血清流行率仍然较低(10% - 57%),而符合MCV1接种条件的儿童(9 - 17个月)血清流行率较高(68% - 91%)。成人麻疹血清流行率超过96%。风疹血清流行率呈现类似模式,88%以上为成人。在开展麻疹 - 风疹运动后,符合条件儿童的麻疹血清流行率从92%增至96%,风疹血清流行率从45%增至82%。
在12年期间,麻疹的人群免疫力显著提高,表明免疫规划绩效有所改善。为减少对频繁补充免疫活动的依赖,应努力优化常规剂量的接种时间和覆盖率,并特别确保提高MCV2的覆盖率。风疹疫苗的引入对儿童免疫力产生了积极影响。维持这种免疫力对于预防老年人群中可能出现的免疫空白至关重要,因为这可能会增加婴儿患先天性风疹综合征(CRS)的风险。